Best Life Sciences Companies in Quebec City, Canada
The 46 best Life Sciences companies in Quebec City, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Genizon BioSciences.
Our analysis of 50 Life Sciences companies
$27.5b in tracked funding; 76% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Quebec City
| # | Company | Last round | Disclosed funding | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 9Bio Therapeutics Developer of computationally-guided cancer therapies | — | — | Unfunded | Henrique Carvalho Co-Founder & CEO | 2 | WordPress Block EditorWordPressMySQL+16 | — | 1 award |
| 2 | Adenine BioComputing Scientific computing for the life sciences | — | — | Deadpooled | Saiho Yuen CEO & Director | — | — | — | — |
| 3 | Axcan Pharma Developer of drugs to treat gastrointestinal problems | — | — | Funding Raised | Leon Gosselin Co-Founder | — | — | 30 patents Gastrointestinal cleansing agents and formulations; high-dose ursodeoxycholic acid for NASH therapy. | — |
| 4 | BEO ITS Developer of medical devices and vaccines for infectious diseases | — | — | Acqui-Hired | Nickolas Tabraue CEO | — | — | — | — |
| 5 | bioSensAll Provider of a technology for GPCR-centric drug discovery | — | — | Unfunded | Pascal Neuville CEO | — | — | — | — |
| 6 | Bodycad Custom orthopedic implants software solutions and manufacturing | — | — | Unfunded | — | 27 | WordPressMySQLPHP+17 | — | 1 launch |
| 7 | DiagnoCure Molecular Diagnostics for Cancer | — | — | Deadpooled | — | 11 | — | 43 patents Molecular diagnostic assays for prostate and gastrointestinal cancer using RNA biomarkers. | — |
| 8 | Duoject Drug delivery and infusion sets | — | — | Unfunded | — | — | — | 229 patents Single-use multi-dose injection and reconstitution devices for sterile drug delivery | — |
Top 12 Life Sciences companies in Quebec City
#1
Series B · Quebec City, Quebec · founded 2007 · 36 employees$40.4Mraised▾
Feldan is developing regenerative medicine therapeutic applications based on Feldan’s proprietary technology. The company has developed Feldan Shuttle, a protein-based technology platform that directly delivers proteins – such as nucleases or transcription factors - inside cells to specific cellular compartments. The Shuttle can overcome obstacles faced by nucleic acid delivery for therapeutic use by decreasing the regulatory process and accelerating the translation of discoveries into clinical applications. The Shuttle also allows enables the development of in-house medical applications as well as in collaboration with partners.
- Apr 2025Series B—
- Feb 2025Series B—
- Sep 2024Series B$21M
- Jun 2023Series B$16.5M
#2
Public · Quebec City, Quebec · founded 2013 · 7 employees$11.5Mraised▾
Developer of drugs for inflammatory diseases and dermatology. The flagship product, Thykamine, has shown anti-inflammatory and anti-oxidant properties, as per company claims, and is currently under development for the treatment of ulcerative colitis, atopic dermatitis, eczema, and psoriasis. The company also develops cosmetic products which include anti-aging products, and sun care products for women and men.
- Aug 2025Post IPO$1.7M
- Mar 2024Post IPO$166K
- May 2023Post IPO$889.6K
- Nov 2021Post IPO$2.3M
#3
Seed · Quebec City, Quebec · founded 2018 · 26 employees$4Mraised▾
Developer of non-invasive ocular oximetry technologies. The company offers its propriety technology for the early detection of ocular disease. The company offers full light spectrum technology to measure the oxygen in ocular and to measure the biomarker in the eye and information on the metabolic state of the eye.
- Apr 2025Seed$984.7K
- Aug 2021Seed$4M
#4
Funding Raised · Quebec City, Quebec · founded 2018$284.7Kraised▾
Digital radiotherapy dosimetry solutions for providers. The company has developed dosimetry measurement tools like 'HS-RP200' and 'HYPERSCINT' for medical physicists. It has features for real-time dosimetry, a portable modular platform, customized probes, and more.
- Nov 2025Conventional Debt$284.7K
#5
Seed · Quebec City, Quebec · founded 2020 · 8 employees$4.1Mraised▾
Developer of 3D cell culture products for drug discovery. The company is developing next-generation technologies for drug discovery and life-saving therapies. The company's product line inlcudes ChromaLive Non-Toxic Dyes, hydrogel for 3D cultures, and PrimaFeed defined culture medium.
- Jun 2024Seed$3M
- Feb 2022Seed$1.1M
#6
Deadpooled · Quebec City, Quebec · founded 1999$129.6Mraised▾
Genizon Biosciences discovers genes and biomarkers in common diseases using genome-wide association studies (GWAS), using its proprietary technology platform and access to patients from the Quebec Founder Population. The company shut its operations in 2011 as it was unable to raise funding, possibly due to competing technologies.
- Jan 2008Series E$30.8M
- Feb 2007Series D$8.4M
- Mar 2006Series C$12M
#7
Public · Quebec City, Quebec · founded 2015 · 4 employees$11.6Mraised▾
Ortho Regenerative Technologies is an orthopedic company developing therapeutic tissue repair devices to improve surgeries. The company is developing products for indications including Rotator Cuff , Meniscus, Articular Cartilage, OA Pain, Other ligament/ tendon, and Nucleus Pulposus. The company is developing its products based on, RESTORE technology, simple to use surgical adjunct that is designed to assist in the repair of hard to heal injuries.
- May 2022Grant (prize money)$500K
- Feb 2022Post IPO$2.6M
- Nov 2021Post IPO$1.2M
- Aug 2020Post IPO$2.5M
#8
Funding Raised · Quebec City, Quebec · founded 2006 · 52 employees$85Mraised▾
Endoceutics is a Canadian, drug discovery and development company focusing on women's health and hormone-sensitive cancer prevention and treatment. In Nov.2016, Endoceutics received FDA approval for Intrarosa for the treatment of dyspareunia, a symptom of vulvovaginal atrophy due to menopause. It is also developing non-estrogen-based therapies for sexual dysfunction and the other symptoms of menopause, including hot flushes, osteoporosis, muscle loss, and type 2 diabetes. Endoceutics has five Phase III product candidates addressing large market opportunities and two Phase I/II product candidates.
- Jan 2017Venture Debt$85M
#9
Acquired · Quebec City, Quebec · founded 2003 · 18 employees$14.6Mraised▾
Manufacturer of optical sensors. It designs and develops optical sensors for the oil, gas, and healthcare industries. It helps measure interventional cardiology, as well as sensors and signal conditioners for temperature, pressure, strain, and deformation measurement in harsh environments.
- Jun 2021Post IPO—
- May 2016Post IPO$5M
- Jan 2016Post IPO$99.3K
- Feb 2014Post IPO$8.5M
#10
Acquired · Quebec City, Quebec · founded 1999 · 600 employees$49.7Mraised▾
Medicago is a developer of vaccines to treat pandemic and seasonal influenza. The company develops its vaccines based on its proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, H1N1 VLP vaccine for Influenza A/California/04/09 virus; and seasonal influenza vaccines and is in phase 3 of the clinical trial. The company has collaboration agreements with Viridis S.A.; Genopole Bio park to manufacture pandemic and seasonal influenza vaccines, and Philip Morris Int. to produce a therapeutic protein with a human-compatible glycosylation pattern.
- Sep 2011Series B$24.2M
- May 2010Series A$9.5M
- Sep 2008PE$16M
#11
Seed · Quebec City, Quebec · founded 2014 · 4 employees$12.2Mraised▾
Developer of colon-specific anti-inflammatory therapy for ulcerative colitis. The company has developed a proprietary Gastro-Intestinal-Induced Anti-inflammatory technology (GiiAnt), which develops potent anti-inflammatory agents with a colon-specific carrier covalently bound to the active moiety in a way that the carrier is cleaved off locally by the large intestine microbiota. The company's pipeline includes GT-2108 is a gut-restricted, colon-specific PDE4 prodrug inhibitor, and GT-1908 for Crohn’s Disease treatment.
- Jun 2021Seed$1.2M
- May 2021Seed$11M
#12
Funding Raised · Quebec City, Quebec · founded 1989 · 124 employees$3Mraised▾
Provider of Track and Trace solutions for the pharma, medical device, and healthcare industries. The company's proprietary and customized solutions help clients in measuring, inspecting, controlling, and tracking their products. They offer inspection and serialization solutions for the global pharmaceutical industry through their expertise in the fields of engineering, optics, electronic innovation, data processing, mechanics, and robotics. They provide software platform OPTEL Certa to optimize the dispensing solutions for pharmacies and other healthcare organizations.
- Jan 2023Unattributed—
- May 2021Grant (prize money)$3M
- PE—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Canada
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 990 Canada-affiliated papers.
- Ministry of Agriculture118
- Ministry of Education70
- University of Toronto61
- McGill University60
- Agriculture and Agri-Food Canada58
- Gene3→32
- Mutant2→13
- Genome2→12
- Transcription factor2→11
- Transcription (linguistics)1→9
- Gene2→40
- Fermentation1→12
- Antimicrobial1→9
- Population1→9
- Agriculture1→8
- Agriculture3→10
- Antibiotic resistance3→10
- Antimicrobial1→6
- Human health2→7
- Microbiome2→6
Where biotechnology is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in Canada
Canada biotechnology patent filing is accelerating — 18,553 filings from 8,000 assignees (2016–2025), led by UNIV British Columbia, UNIV Health Network, NAT RES Council Canada; annual filings 1716→1734.
- UNIV British Columbia1568
- UNIV Health Network1207
- NAT RES Council Canada900
- UNIV Alberta749
- CA NAT Research Council697
- Medicago680
- UNIV Saskatchewan597
- Zymeworks594
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.